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SOX2 is a gene that encodes for a transcription factor belonging to the SOX gene family and contains a high-mobility
group (HMG) domain, which permits highly specific DNA binding. Consequently, SOX2 functions as an activator or
suppressor of gene transcription. SOX2 has been described as an essential embryonic stem cell gene and
moreover, a necessary factor for induced cellular reprogramming. SOX2 research has only recently switched focus
from embryogenesis and development to SOX2’s function in disease. Particularly, the role of SOX2 in cancer
pathogenesis has become of interest in the field. To date, studies have shown SOX2 to be amplified in various
cancer types and affect cancer cell physiology via involvement in complicated cell signaling and protein-protein
interactions. Recent reviews in this field have highlighted SOX2 in mammalian physiology, development and
pathology. In this review, we comprehensively compile what is known to date about SOX2’s involvement in cancer
biology, focusing on the most recent findings in the fields of cellular signaling and cancer stem cells. Lastly, we
underscore the role of SOX2 in the clinic and highlight new findings, which may provide novel clinical applications
for SOX2 as a prognostic marker, indicator of metastasis, biomarker or potential therapeutic target in some cancer
types.
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The SOX family is a group of related transcription factors
that have demonstrated their importance in developmen-
tal and stem cell biology. In 1990, pioneering research
discovered the mammalian testis-determining factor and
the gene was termed Sry due to its corresponding location
in the sex-determining region on the Y-chromosome [1,2].
Sry contains a distinctive high-mobility group (HMG)
domain, which permits precise DNA recognition and bin-
ding. Proteins that contain the HMG domain with amino
acid similarity of 50% or higher to the HMG domain of Sry
are termed SOX (abbreviation for Sry-related HMG box)
proteins [3-5]. Known functions of these proteins range
from regulation of embryonic development and stem cell
maintenance to homeostasis in adult tissues [6].
In 1994, the SOX2 gene, one of the SOX family mem-
bers, was discovered and characterized in humans [7].* Correspondence: j.utikal@dkfz.de
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reproduction in any medium, provided the origThe SOX2 gene is located on chromosome 3q26.3–q27,
belongs to the SOXB1 group and encodes for a protein
consisting of 317 amino acids (Figure 1A) [7,8]. SOX2 is
comprised of three main domains: N-terminal, HMG
and transactivation domain (Figure 1B). SOX2 research
thus far has heavily emphasized its crucial role in stem
cell maintenance, lineage fate determinant and a neces-
sary factor to reprogram somatic cells back towards
pluripotency [5,9,10]. In disease, SOX2 alterations have
been associated with developmental maladies, such as
anophthalmia-esophageal-genital (AEG) syndrome, which
occurs when there is a heterozygous mutation of SOX2
that leads to abnormal development of ectodermal and
endodermal tissues [11]. Aside from developmental
diseases, accruing research has strongly associated
SOX2 with cancer.
Here, we consolidate SOX2’s role in cancer and provide
a comprehensive overview of the field, focusing on the la-
test research that has implicated SOX2 in cancer biology
and in the clinic. SOX2 has been shown to be associated
with numerous cancer types, even described in some casesis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
Figure 1 SOX2 homology, structure and protein function. (A) SOX2 belongs to the SOXB1 of SOX proteins. There is large homology between
the SOXB1 group and they all contain three major domains: N-terminal, HMG and C-terminal domain. (B) SOX2 protein domains play several
functional roles. The HMG domain of SOX2 remains fairly conserved between homo sapiens, Mus musculus and Danio rerio (Swiss-Prot: P48431,
P48432, Q6P0E1). The HMG domain also serves as potential binding sites for protein partners. Moreover, nuclear import signals (NIS) and nuclear
export signals (NES) bind to the HMG domain regulating SOX2 itself. Lastly the transactivation domain functions as the region responsible for
promoter binding, which in turn leads to activation or repression of target genes.
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promoting oncogenic signaling and maintaining cancer
stem cells. Lastly, we investigate recent work that has
highlighted the role of SOX2 in the clinic, particularly its
influence on prognosis, therapy resistance and potential
therapeutic interventions.Review
SOX2 and cancer biology: current research
SOX2 amplification in cancer
Tumor development occurs when a cell accumulates
genetic alterations that modify normal cell cycle pro-
gression. There are several means of genetic aberrations
including gene deletions or gene amplification. Gene
amplification is defined as a copy number increase of a
particular chromosomal region. SOX2 amplification is
due to multiplication of the 3q26.3 gene locus [12,13].
SOX2 amplification has previously been found in several
cancer types including glioblastoma, small-cell lung
cancer (SCLC) and many forms of squamous cell
carcinoma (SCC) [12,14-20]. A summary of SOX2 ampli-
fication in various cancer types with corresponding refe-
rences can be found in Table 1.The latest SOX2 studies have focused on the co-
amplification of SOX2 with other critical genes. Justilien
and colleagues revealed the co-amplification of two on-
cogenes, PRKCI and SOX2, is responsible for the cancer
stem cell phenotype seen in lung squamous cell carci-
noma (LSCC) [61]. Moreover, another study performed
FISH analysis in 447 resected non-small cell lung cancer
(NSCLC) tissue samples and SOX2 amplification was
associated with increased gene copy number of FGFR1
and PI3KCA genes [62].
SOX2’s involvement in cancer cell physiology varies
between cancer types
As described by Hanahan and Weinberg, cancer is a
disease characterized by determined hallmarks some of
which are: sustained proliferative signaling, activation of
invasion and metastasis, and evasion of cell death [73].
Studies have strongly associated SOX2 to these respec-
tive cancer hallmarks and thus far SOX2 has been
shown to promote cellular proliferation (breast, prostate,
pancreatic and cervical cancers) [21,28,57,58], evade apop-
totic signals (prostate, gastric cancer and NSCLC)
[37,58,63] and promote invasion, migration and metas-
tasis (melanoma, colorectal, glioma, gastric, ovarian
Table 1 Summary of SOX2 amplification and functions in cancer
Cancer type SOX2 gene
amplification
SOX2 function Pathway/Process References





Cervical Unknown ↑cell proliferation, ↑clonogenicity, ↑tumorigenicity Unknown [28]
Colorectal Unknown ↑↓cell proliferation, ↑metastasis, ↑senescence, ↑autophagy,





Esophageal SCC Yes ↑cell proliferation, ↑tumor growth ↑Akt/mTORC1, ↑STAT3 [17,34-36]




Yes ↑promoter hypomethylation, ↑invasion, ↑migration, ↑self-




Unknown ↑invasion, ↑sphere formation ↑EMT [47]
Layngeal Unknown ↑ invasion/migration ↑MMP-2 ↑PI3L/AKT/mTOR [48]
Melanoma Unknown ↑invasion, ↑tumor volume, ↑self-renewal CSCs ↑Hedegehog-GLI signaling [49-53]
Oral SCC Yes Unknown Unknown [20]
Osteosarcoma Unknown ↑self-renewal CSCs, ↑tumorigenicity, ↑dedifferentiation ↓WNT/ β-CATENIN [54]
Ovarian Unknown ↑migration, ↑invasion, ↑colony formation Unknown [55,56]
Pancreatic Unknown ↑cell proliferation, ↑stemness/dedifferentiation ↑EMT [57]
Prostate Unknown ↑self-renewal CSCs, ↑cell proliferation, ↑cell survival,






SCLC, Lung SCC, lung
adenocarcinoma, NSCLC
Yes ↑cell proliferation, ↑cell survival, ↓apoptosis, ↑migration,
↑anchorage-dependent growth, ↑self-renewal CSCs,




Sinonasal Yes Unknown Unknown [71]
Transitional cell
Carcinoma
Unknown ↑alternative splicing Unknown [72]
SOX2 has been shown to be amplified and functionally relevant in various cancer types. SOX2 in cancer functions through multiple mechanisms that vary
depending on the cancer type. However, in most cases, SOX2 has been shown to increase cell proliferation, invasion, migration, metastasis and self-renewal of
CSCs. In addition, some of these phenotypes have been linked to particular oncogenic pathways, including WNT/β-CATENIN, EGFR, mTOR and HH signaling.
↑ = Promotes/Improves.
↓ = Suppresses/Inhibits.
↑↓ = Conflicting research.
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We summarized SOX2 amplification and resulting al-
terations in cellular functions in all cancer types in
Table 1 and showed examples of SOX2’s role in oncogenic
signaling in Figure 2. Below we highlight a few functional ex-
amples of SOX2 in cancer before we review the latest SOX2
research in different aspects of cancer physiology including:
cellular proliferation, apoptosis and invasion/migration/
metastasis. For a complementary and closer examination
into SOX2 and oncogenic signaling, protein-protein inter-
actions and miRNAs see review by Liu et al. [74].
Cellular proliferation is tightly regulated by SOX2 in
many cancer types. SOX2 knockdown in pancreatic
cancer cells resulted in cell growth inhibition through
cell cycle arrest, not apoptosis, via the transcriptional
induction of p21Cip1 and p27Kip1 [57]. When SOX2 wasoverexpressed, cell proliferation was promoted through
cyclinD3 (CCND3) transcriptional induction and allowed
further S-phase entry (Figure 2B) [57]. Recently, Hütz and
colleagues confirmed this in gastric cancer [37]. SOX2 was
functionally inhibited via cellular transfection with a
tetracycline-inducible C-terminally truncated version of
SOX2, termed dnSOX2. Despite lacking the transacti-
vation domain, dnSOX2 could bind SOX2 recognition
sites on DNA and compete with wild-type SOX2. This
inhibition led to the decrease in cellular proliferation in
AZ-521 cells and further analysis using a RNA gene
expression microarray, revealed an upregulation of p21
and downregulation of Δp63 (splice variant of p63) [37].
Additionally, Fang and colleagues found in LSCC,
SOX2-silencing inhibited cellular proliferation via the



















































A Influence of SOX2 on Cellular Processes










































































Figure 2 (See legend on next page.)
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Figure 2 Influence of SOX2 on oncogenic-related processes and transcription. (A) SOX2 is an important regulator of cellular processes
related to cancer. Some of these processes include but aren’t limited to WNT/β-CATENIN signaling, EMT and JAK/STAT3 signaling. In most cases,
SOX2 functions downstream in the nucleus. SOX2’s activity leads to further downstream effects and finally alters cellular phenotypes such as
cellular survival, invasion and metastasis. (B) SOX2 is typically regulating processes downstream on a transcriptional level. There are several
examples of SOX2 influencing cancer phenotypes by repressing or activating particular target genes including EMT promotion via binding to the
promoter regions of SNAIL, SLUG and TWIST. Therefore, SOX2 functions in cancer as a key transcription factor.
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was found to transcriptionally repress the BMP4 pro-
moter. The authors therefore suggest that BMP4 is play-
ing a tumor suppressor role in LSCC, while SOX2
repression of BMP4 transcription causes cell growth
[64]. It’s important to note that the involvement of
SOX2 in cell proliferation has been controversially dis-
cussed in colorectal and gastric cancer [30,31,37,38].
The contradictory effect of SOX2 in cell proliferation
suggests that SOX2 plays a differential role depending
on the type of cancer (Figure 2B).
SOX2 also plays an important role in evading apoptotic
signals. In prostate cancer, in vitro and in vivo xenograft
experiments using DU145 SOX2-overexpressing cells in
NOD/SCID mice revealed that SOX2 caused an increase
in apoptotic resistance by decreasing store-operated Ca2+
entry via repressing ORAI1 expression (Figure 2) [58].
Equivalently, upon silencing of SOX2 in NSCLC cell lines,
apoptosis was induced [63]. Hütz and colleagues, in
addition to proliferation analysis, investigated apoptosis
using, caspase 3/7 assays performed in AZ-521 gastric
cancer cells [37]. After 48 hours of SOX2 inhibition, nearly
60% of cells were apoptotic compared to only 20 – 40% of
the control cells [37]. These studies prove SOX2’s involve-
ment in apoptosis inhibition and therefore in direct pro-
motion of uncontrolled cell growth.
Finally, research has indicated that SOX2 is a novel
regulator of cell invasion, migration and metastasis. For
example in melanoma, SOX2 knockdown in A2058 cells
resulted in a 4.5-fold decrease in invasion in vitro and
adopted this phenotype via the upregulation of matrix
metalloproteinase (MMP)-3 [49]. Likewise in colorectal
cells, SOX2 was involved in cellular migration and inva-
sion in vitro, but mediated these effects through MMP-2
[29]. This invasive phenotype was also confirmed in ma-
lignant glioma, since siRNA-mediated downregulation
of SOX2 resulted in a significant decrease in migration
and invasion capabilities [15]. Moreover SOX2 over-
expression in the SOX2-negative glioma cell line U-87
resulted in a significant increase in the number of mi-
gratory and invasive cells [15]. Numerous gain and loss
of function studies in several cancer types (gastric
cancer, ovarian cancer and hepatocellular carcinoma) re-
inforced the link between SOX2 and cellular invasion and
migration [15,37,47,55]. Recently, Yang and colleaguesshowed SOX2’s involvement in promoting invasion
and migration in laryngeal cancer cells through the
induction of MMP-2 and the PI3K/AKT/mTOR path-
way (Figure 2A) [48].
SOX2 and cancer stem cells: current research
Many tumors are derived from a single cell that has
undergone malignant transformation through the acqui-
sition of genomic aberrations, e.g. gene amplification,
mutations or other mechanisms [75]. Clonal expansion
of cells with tumorigenic properties is the next step to-
wards tumor initiation. These selected cells have the
ability to evade normal cell cycle checkpoints, rapidly
proliferate and invade tissues [73,75]. The orchestration
of tumor initiation and maintenance has been shown in
some cancers to be driven by cancer stem cells (CSCs),
also termed tumor-initiating cells or cancer stem-like
cells. These CSCs may acquire tumor-initiating and self-
renewal properties through similar molecular mecha-
nisms governing cellular reprogramming [76]. Evidence
has linked induced cellular reprogramming to cancer
and led to the assumption that CSCs may arise via a
reprogramming-related mechanism [77-79]. The reacti-
vation of stem cell-associated markers or pluripotency
factors may cause dedifferentiation and a more stem
cell-like state [76]. Sussman and colleagues discovered
that the ubiquitin-specific protease 22 (USP22) is respon-
sible for controlling the cellular transition from stemness
towards differentiation [80]. Moreover they found USP22
represses the SOX2 promoter in order to control the em-
bryonic stem cell transition from self-renewal to differenti-
ation [80] Therefore, not only is SOX2 an essential stem
cell marker but its suppression is mandatory for cellular
differentiation. For these reasons, SOX2 has been heavily
investigated in CSCs in several cancer types.
SOX2 regulates self-renewal and maintenance in cancer
stem cell populations
SOX2 has shown to increase CSC markers in ovarian,
pancreatic, lung cancer, but research also has proven its
function in self-renewal [57,81,82]. Self-renewal capacity
of a CSC is critical and enables the maintenance of
the CSC subpopulation within a tumor and SOX2 has
shown to mediate this in breast, gastric, ovarian, pros-
tate cancer, glioma, osteosarcoma, lung adenocarcinoma
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tric cancer using siRNA-mediated SOX2 knockdown,
found reduced spheroid colony formation and increased
apoptosis within sphere cells, highlighting the importance
of SOX2 in self-renewal capacity [83]. In prostate cancer
stem cells, the activation of EGFR signaling increased
SOX2 expression and the self-renewal capacity [59]. Singh
and colleagues showed similar results in NSCLC, when
siRNA-mediated SOX2 knockdown led to a 2.5-fold re-
duction in sphere formation [65]. Moreover, EGFR/Src/
Akt signaling influenced SOX2 protein expression since
during EGFR or SRC inhibition using gefitinib or BIBW,
respectively, levels of SOX2 were considerably decreased
[65]. Taken together, SOX2 mediates self-renewal of CSCs
through EGFR signaling in at least two cancer types and is
a major mediator of self-renewal in several cancers through
mechanisms that remain unclear.
Recent CSC studies have concentrated on SOX2 and
its mechanisms in cancer stem cell maintenance and
regulation. Santini and colleagues investigated SOX2 in
melanoma initiating cells and Hedgehog-GLI (HH-GLI)
signaling [50]. They functionally showed that the ectopic
expression of SOX2 in vitro caused enhanced self-renewal
capacity in melanoma cells. Moreover, GLI1 and GLI2
downstream transcription factors of HH-GLI Signaling
were able to bind to the proximal promoter of SOX2 in
primary melanoma cells in chromatin immunoprecipita-
tion (ChIP) studies and therefore SOX2 is regulated by
HH signaling [50]. To a similar extent, Justilien and
colleagues heavily investigated Hedgehog (Hh) acyltrans-
ferase (HHAT) in LSCC and found that not only are
PRKCI and SOX2 coamplified and cooperate in LSCC
but also SOX2 becomes phosphorylated by Protein
Kinase Cι (PKCι) [61]. Next, phosphorylated SOX2 is
recruited and required for HHAT expression and
therefore maintenance of the stem-cell phenotype. The
authors provide evidence that the coamplifcation of
both oncogenes is required to activate the PKCi-SOX2-
HHAT signaling axis which impels the stem cell pheno-
type. Further work is being done on establishing PKCι
inhibitors for LSCC treatment [61].
Lastly, a recent publication by Favaro and colleagues
proved that SOX2 is required for in vitro CSC mainten-
ance in a high-grade oligodendroglioma mouse model
[43]. Oligodenrogliomas were generated in mice via the
transduction of PDGF-B-IRES-GFP-encoding retrovirus
within the brain at embryonic day 14.5. Additionally
these embryos carried a homozygous SOX2flox mutation,
which allowed authors to excise SOX2 using lentiviral
Cre recombinase virus. Wild-type oligodendroglioma cells
from mentioned mouse model were transplanted into the
brain of C57/Bl6 mice, which generated lethal tumors.
However, when SOX2-deletion cells were transplanted
into C57/Bl6 mice they remained tumor free [43]. Thiselegant study proved the obligatory function of SOX2 in
oligodendroglioma tumor initiation. The requirement of
SOX2 in oligodendroglioma suggested possible thera-
peutic intervention.Correlations between SOX2 and clinical outcome: current
research
SOX2 has proven its functional role in various aspects
of cancer biology. Research on SOX2 has also investi-
gated its importance in the clinic in respect to disease
prognosis, relapse, therapy resistance, comprehensive
summary in Table 2. The ability to improve reliability
of diagnosis or prognosis of a cancer patient can have
immense impact on survival and better understanding
of the disease. For example, 162 esophageal squamous
cancer patients were analyzed for SOX2 and OCT3/4 ex-
pression and high expression of both markers was associ-
ated with higher histological grade or TNM stage (p <
0.001 for both factors), demonstrating their link to dedif-
ferentiation in these tumors (Table 2) [84]. Furthermore, a
significant correlation between high SOX2 levels and
decreasing patient survival was shown (p < 0.001) [84].
Recently, Forghanifard and colleagues revealed that
stemness state regulators SALL4 and SOX2 are over-
expressed in 64 esophageal cancer samples and co-
overexpression correlated with depth of tumor invasion
and metastasis [85]. Again, contrasting results for
SOX2’s role in the clinic were highlighted in lung cancer
(including NSCLC and SCLC), where SOX2 was corre-
lated to improved survival and better patient outcome
[62,67,68,86-88]. These opposing outcomes in the clinic
further underscore the differing role of SOX2 in varying
cancer types.SOX2’s influence on therapy resistance
Drug resistance has been associated with expression of
various pluripotency markers, including NANOG, OCT4
and SOX2, since these genes typically lead to a decrease
in differentiation status [68]. In breast cancer, silencing
SOX2 not only reduced the size of the CSC population
but also restored tamoxifen sensitivity, suggesting tam-
oxifen resistance is primarily driven by SOX2 in breast
CSCs [89]. Recently, Dogan and colleagues investigated
SOX2 and EGFR inhibitors in lung adenocarcinoma cell
lines [68]. When a SOX2 knockdown using shRNA was
performed in HCC827 cells, decreased proliferation was
observed along with increased sensitivity to erlotinib.
Furthermore, upon the treatment with PI3K/AKT inhibi-
tors, SOX2 expression decreased [68]. Therefore, targeting
SOX2 in EGFR-mutant tumors may be therapeutically
beneficial; however more direct targeting strategies need
to be further developed.
Table 2 Clinical relevance of SOX2
Cancer type Function in the clinic References
Breast
Promotes Tamoxifen resistance via WNT signaling activation in CSCs [21,27,89]
ZF-based ATF therapy effective for downregulation of SOX2
Expression correlates with TNM stage and histological grade
Colorectal
Prognostic marker for metastasis [29,32]
Associated with poor patient prognosis
Associated with distant metastasis and lymph-node metastasis
Esophageal
Co-expression with OCT3/4 significantly associated with higher histological stage [84,85,90]
Co-expression with OCT3/4 correlated to poorer survival
Co-expression with SALL4 correlates to depth of tumor invasion and metastasis
CD44 and SOX2 is correlated to poor survival
Gastric
Associated with poor prognosis [38,41]
SOX2 methylation correlates to significantly shorter survival time
Predicts immunotherapy response
Hepatocellular carcinoma
Expression correlates with metastasis [47]
Expression correlates with low survival rate
Lung, NSCLC, Squamous cell lung cancer
Associated with better survival independent of histological subtype [62,67,68,86-88]
Expression is a positive prognostic marker
SOX2 amplification and upregulation are frequent events linked to favorable prognosis
Important tumor-associated antigen
Associates SOX2-positive T-cells to patient response to immunotherapy
Increases resistance to EGFR inhibitors
Melanoma
Novel biomarker for normal skin subpopulation responsible for tumorigenesis [52,53]
SOX2 and Nestin differentiate between nevi and melanoma metastasis
SOX2 and Nestin powerful diagnostic tools
Ovarian
Expression directly proportional to higher degree of malignancy [56,82]
Responsible for CSC therapy resistance
Rectal
Predicts poor distance recurrence for preoperative CRT patients [91]
Predicts poor prognosis for preoperative CRT patients
Sinonasal SOX2 amplification identifies carcinomas more likely to relapse [71]
The role of SOX2 in the clinic has been studied and expression has been correlated to patient survival, prognosis and therapy. SOX2 has been shown to play
different roles depending on cancer type and can predict both better and worse outcomes for patients. Moreover, SOX2 has proven its use as a prognostic
marker in melanoma, colorectal, gastric and lung cancer.
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Improving cancer therapy options in the clinic remains a
priority. SOX2 has shown its potential to become a useful
biomarker in the clinic for some cancer types, for both
staging tumors and identification of the CSC subpopula-
tions (Table 2). Utilizing SOX2 for cancer therapy may
open a window to new therapeutic opportunities. SOX2
does not lend itself for direct therapeutic intervention due
to its importance in transcriptional cellular function and
targeting SOX2 may have dozens of unwanted complica-
tions. However, targeting signals upstream or downstream
of SOX2 may prove beneficial in cancer therapy. For ex-
ample, as mentioned above in NSCLC and prostate CSCs,
SOX2 relies heavily on EGFR signaling for mediating self-renewal in CSCs. Currently, anticancer drugs are on the
market targeting EGFR, such as gefitinib and erlotinib,
and may be useful in inhibiting SOX2’s downstream self-
renewal effects, however resistance to these therapies is
nearly inevitable and needs to be overcome. Therefore,
further targeting SOX2 in EGFR-mutant cancer with
PI3K/AKT inhibitors, as shown above in lung adeno-
carcinoma cell lines, may yield better results [68].
Recently published studies have attempted to tackle
SOX2 therapy and its implications. Favaro and colleagues,
who performed the oligodenroglioma studies in mice, fur-
ther examined SOX2 peptides for immunotherapy treat-
ment in mice [43]. The C57BL/6 N mice were injected
with wild-type oligodendroglioma cells from established
Weina and Utikal Clinical and Translational Medicine 2014, 3:19 Page 8 of 10
http://www.clintransmed.com/content/3/1/19mouse model and upon vaccination with SOX2 peptides,
significant delay in tumor growth was observed [43]. Simi-
larly, Polakova and colleagues developed an experimental
DNA vaccine against SOX2 [92]. In this study, C57BL/6
and BALB/c mice were immunized with DNA vaccine and
found a significant SOX2-specific activation of lympho-
cytes. However, when the antitumor effects were exam-
ined using TC-1/B7 (derived from lung cancer cell line
TC-1) cells the DNA vaccination did not prevent tumor
development even though it was able to significantly
reduce tumor growth [92].
Conclusion: SOX2 in the future
SOX2 has proven not only to be an essential embryonic,
reprogramming and development-associated gene but
has begun to leave its footprint in the field of oncology.
SOX2 is intricately involved in many cancer-associated
processes such as cell proliferation, evading cellular apop-
tosis and metastasis via interactions with EGFR signaling
and several other oncogenic pathways and processes.
Moreover, current and ongoing SOX2 CSC research has
emphasized the importance of investigating early devel-
opmental genes, since they may be responsible for self-
renewal of CSCs. Lastly, in clinical settings, SOX2 has
shown a heavy influence on patient survival and prog-
nosis. In summary, SOX2 function in cancer has been
accentuated in numerous cancer types in and out of the
clinic and investigating SOX2’s oncogenic course is
important for future prognosis, survival of cancer patients
and possible therapeutic interventions.
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